Heterocytes as inhibitors of leucocyte adhesion and as VLA-4 antagonists

US6838439B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Hans Ulrich Stilz · Frankfurt am Main, DE
• Volkmar Wehner · Bischofsheim a.d.Rhön, DE
• Christoph Huls · Wackernheim, DE
• Dirk Seiffge · Hochheim, DE

Key dates

• Filing date: Nov 29, 2001
• Grant date: Jan 4, 2005
• Expiry date: Jul 16, 2023

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of the formula I which are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 which belongs to the group of integrins. The invention also relates to processes for the preparation of formula I, pharmaceutical compositions containing compounds of formula I, and the treatment or prophylaxis of various diseases caused by or are associated with excess leucocyte adhesion and/or leucocyte migration, as well as diseases associated with cell-cell or cell-matrix interactions, which on interactions of VLA-4 receptors with their ligands play a part of, for example, inflammatory processes, rheumatoid arthritis or allergic disorders.